Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies

实体瘤 医学 妇科癌症 免疫系统 癌症研究 癌症 化疗 内科学 免疫疗法 肿瘤细胞 肿瘤科 抗体 妇科肿瘤学 放射免疫疗法 免疫学 实体瘤疗效评价标准 病理 固体器官
作者
Xiaolin Zhu,Edwin Alexander Alvarez,Sarah E. Umetsu,Jocelyn Chapman,Lee-may Chen,Stefanie M. Ueda,Suzannah Henderson,Phuong Nguyen,Susan Calabrese,Jacky Russell,Julian Aguilar,Simon A. Smith,Neel Shah,Laura Feeney,Jessica Van Ziffle,Michelle L. Turski,Andrew H. Ko,Pamela N. Münster,Alan Ashworth,Eric Andrew Collisson
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:32 (9): 1632-1640 被引量:6
标识
DOI:10.1158/1078-0432.ccr-25-4043
摘要

PURPOSE: ARID1A is frequently mutated in cancer. Motivated by the preclinical synthetic lethality between ARID1A loss and ataxia telangiectasia and Rad3-related (ATR) inhibition, we performed an investigator-initiated phase II study of the ATR inhibitor (ATRi) ceralasertib in ARID1A-deficient solid tumors (NCT03682289). PATIENTS AND METHODS: This was a phase II, Simon two-stage study with a planned sample size of 29 evaluable patients. Eligible patients had locally advanced or metastatic solid tumors with measurable disease by Response Evaluation Criteria in Solid Tumors 1.1 and radiographic progression at study entry. Patients were required to have ARID1A loss as determined by immunohistochemistry analysis of tumor tissue. Patients received ceralasertib 160 mg twice daily on days 1 to 14 every 28 days. RNA sequencing (RNA-seq) and cyclic immunofluorescence were performed on tumor tissue to identify potential biomarkers of treatment response. RESULTS: The confirmed objective response rate (ORR) was 14% among the 29 efficacy-evaluable patients. All four responses, including three complete responses, occurred in endometrioid endometrial carcinoma or ovarian clear-cell carcinoma, with an ORR of 33% and a median duration of response of 33.7 months in this subset. Including one patient with uterine carcinosarcoma who had stable disease, the ORR was 31% among the 13 patients with gynecologic malignancies. Exploratory RNA-seq analysis of pretreatment archival tumor tissue identified upregulated G2-M checkpoint and DNA double-strand break-sensing pathways in patients who responded. Immune profiling revealed tumor immune microenvironment changes associated with the response to ceralasertib. CONCLUSIONS: Ceralasertib monotherapy demonstrated promising antitumor activity in ARID1A-deficient gynecologic malignancies. Tumor molecular and immune correlates may inform the further development of ATRis in this patient population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
hang发布了新的文献求助10
刚刚
QNDXX发布了新的文献求助10
刚刚
ln完成签到,获得积分10
刚刚
zouxinxin发布了新的文献求助30
1秒前
没有答案完成签到,获得积分10
2秒前
zys发布了新的文献求助10
2秒前
2秒前
小蘑菇的应助被BAEKHYUNLUCKY采纳,获得10
3秒前
漂亮灵阳完成签到,获得积分10
3秒前
炸鱼排完成签到,获得积分10
4秒前
5秒前
斯文的日记本完成签到,获得积分10
5秒前
小小研究僧完成签到,获得积分20
6秒前
6秒前
SCW发布了新的文献求助10
7秒前
鸭不抗揍完成签到 ,获得积分10
7秒前
7秒前
7秒前
8秒前
9秒前
斯文败类的应助被激动的项链采纳,获得10
9秒前
10秒前
10秒前
12完成签到,获得积分10
10秒前
10秒前
梦梦的应助被zys采纳,获得10
11秒前
12秒前
荼蘼发布了新的文献求助10
12秒前
Owen的应助被GamAooL采纳,获得10
12秒前
ubless607发布了新的文献求助30
12秒前
zzz发布了新的文献求助10
13秒前
13秒前
14秒前
15秒前
高高靳发布了新的文献求助10
16秒前
17秒前
nini发布了新的文献求助10
17秒前
小孟完成签到,获得积分10
18秒前
独特的青曼完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241